Cite
Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study.
MLA
Bunch, T.Jared, et al. “Rationale and Design of the Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard Study.” Clinical Cardiology, vol. 42, no. 5, May 2019, pp. 506–12. EBSCOhost, https://doi.org/10.1002/clc.23181.
APA
Bunch, T. J., Jacobs, V., May, H., Stevens, S. M., Crandall, B., Cutler, M., Day, J. D., Mallender, C., Olson, J., Osborn, J., Weiss, J. P., & Woller, S. C. (2019). Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. Clinical Cardiology, 42(5), 506–512. https://doi.org/10.1002/clc.23181
Chicago
Bunch, T Jared, Victoria Jacobs, Heidi May, Scott M Stevens, Brian Crandall, Michael Cutler, John D Day, et al. 2019. “Rationale and Design of the Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard Study.” Clinical Cardiology 42 (5): 506–12. doi:10.1002/clc.23181.